UNSPSC 51351634: Conjugated estrogens/medroxyprogesterone acetate

Conjugated estrogens/medroxyprogesterone acetate (CEs/MPA) is a combination product of conjugated estrogens (Premarin), an estrogen, and medroxyprogesterone acetate (Provera), a progestogen, which is used in menopausal hormone therapy for the treatment of menopausal symptoms.

UNSPSC 51351634 Conjugated estrogens/medroxyprogesterone acetate is a Commodity code that names a specific hormone-replacement pharmaceutical, yet the recent state and local opportunities posted under this code show minimal direct relevance to the code's nominal scope. The recent opportunities instead encompass a broad spectrum of health-care procurement — from emergency medical services software and pharmacy benefit administration to forensic drug analysis standards and opioid-settlement grant administration — with no posted solicitations explicitly seeking conjugated estrogens or medroxyprogesterone acetate products. The mismatch reflects either mis-tagging by issuing bodies or an artifact of how state and local procurement portals classify opportunities. Where pharmaceutical services are being procured, issuing bodies are hospitals and long-term care facilities, county health departments, emergency medical services agencies, and mental-health providers seeking comprehensive drug distribution, pharmacy network participation, or controlled-substance supply management rather than branded hormone-replacement medications.

The most concrete pharmaceutical-specific opportunities are Dane County's RFP for comprehensive pharmacy services to Badger Prairie Health Care Center (due October 22, 2026, with local-vendor preference), West Texas Centers for Mental Health's RFP for prescription and pharmacy services across 23 counties (due August 21, 2026), the City of Tucson Fire Department's RFP for BLS and ALS pharmaceuticals, supplies, and vending systems (due June 24, 2026, federally funded through ARPA and HUD), and Seminole County's competitive bid for naloxone and drug deactivation systems (1,900 units annually, quarterly delivery, due July 26, 2023). These solicitations reflect state and local demand for vendor-supplied drug distribution logistics, inventory management, and compliance infrastructure rather than drug procurement itself. The code's decision value remains unclear given the activity's divergence from the code's stated pharmaceutical identity; firms pursuing actual hormone-replacement product sales should validate whether opportunities correctly map to this code or whether mis-tagging is widespread.